Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE W BODE

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1841297751
CMS profile
265665
Location
ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$299,230.92

514 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 11 of 11; records 501–514 of 514 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE W BODE

NPI 1841297751 · CMS profile ID 265665

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 11 of 11; records 501–514 of 514 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841297751?year=2021&recipient=provider&page=11#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE W BODE, NPI 1841297751, CMS profile ID 265665. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 11 of 11; records 501–514 of 514 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841297751?year=2021&recipient=provider&page=11#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BRUCE W BODE, NPI 1841297751, CMS profile ID 265665. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 11 of 11; records 501–514 of 514 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841297751?year=2021&recipient=provider&page=11#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BRUCE W BODE, NPI 1841297751, CMS profile ID 265665, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 11 of 11; records 501–514 of 514 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1841297751?year=2021&recipient=provider&page=11#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

514 matching records · $299,230.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 514 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 501–514 of 514.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $600.0001/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 860804159 CMS
Xeris Pharmaceuticals, Inc. $2,500.0001/27/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837413459 CMS
Abbott Laboratories $18.8701/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818402979 CMS
Lilly USA, LLC $1,200.0001/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818899915 CMS
Medtronic, Inc. $13.3801/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815593181 CMS
Medtronic, Inc. $3.2301/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815593207 CMS
Amneal Pharmaceuticals LLC $25.0601/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829647337 CMS
SANOFI-AVENTIS U.S. LLC $21.5201/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843425589 CMS
Corcept Therapeutics $15.7801/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837516051 CMS
Novo Nordisk Inc $14.4701/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811549495 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.3901/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819869189 CMS
CeQur Corporation $11.2701/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855400653 CMS
Zealand Pharma US, Inc. $15.9201/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 800225145 CMS
Corcept Therapeutics $18.3801/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837516049 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $386,078.26 618
PY2020 $274,545.53 446
PY2021 $299,230.92 514
PY2022 $246,002.31 438
PY2023 $215,973.36 408
PY2024 $96,919.88 284
PY2025 $14,397.80 129

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,102,284.16 94
PY2024 Recipient $7,070.00 1
PY2024 Principal investigator $2,024,445.57 164
PY2023 Recipient $68,535.26 3
PY2023 Principal investigator $1,833,463.03 150
PY2022 Recipient $19,520.00 1
PY2022 Principal investigator $4,350,201.91 498
PY2021 Principal investigator $2,661,138.98 685
PY2020 Recipient $9,086.00 1
PY2020 Principal investigator $2,034,637.45 179
PY2019 Recipient $58,943.55 3
PY2019 Principal investigator $2,720,578.10 114

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Senseonics, Incorporated $1,676.35 12/11/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851853
Principal investigator 1 Senseonics, Incorporated $91.00 12/11/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851855
Principal investigator 1 Senseonics, Incorporated $45.50 12/11/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851857
Principal investigator 1 Senseonics, Incorporated $150.00 12/11/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851859
Principal investigator 1 Abbott Laboratories $186.00 12/04/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162642
Principal investigator 1 Abbott Laboratories $122.00 12/01/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162504
Principal investigator 1 Abbott Laboratories $248.00 12/01/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162524
Principal investigator 1 Abbott Laboratories $72.00 12/01/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162532
Principal investigator 1 Abbott Laboratories $74.00 12/01/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162554
Principal investigator 1 Abbott Laboratories $79.00 12/01/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162576
Principal investigator 1 Abbott Laboratories $74.00 12/01/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162598
Principal investigator 1 Abbott Laboratories $27.90 12/01/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162620
Principal investigator 1 Abbott Laboratories $186.00 11/20/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162712
Principal investigator 1 Abbott Laboratories $248.00 11/12/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162608
Principal investigator 1 Dexcom, Inc. $13,795.00 11/11/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
MULTI-SESSION EVALUATION OF THE INVESTIGATIONAL DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM IN ADULT PARTICIPANTS No dispute reported 06/30/2026 1250961530
Principal investigator 1 Abbott Laboratories $248.00 11/06/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162540
Principal investigator 1 SANOFI US SERVICES INC. $13,500.00 10/20/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226138058
Principal investigator 1 SANOFI US SERVICES INC. $66,084.20 10/20/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226138061
Principal investigator 1 Abbott Laboratories $216.00 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162442
Principal investigator 1 Abbott Laboratories $222.00 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162444
Principal investigator 1 Abbott Laboratories $222.00 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162446
Principal investigator 1 Abbott Laboratories $38.00 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162448
Principal investigator 1 Abbott Laboratories $610.00 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162450
Principal investigator 1 Abbott Laboratories $256.00 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162452
Principal investigator 1 Abbott Laboratories $4.65 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162454
Principal investigator 1 Abbott Laboratories $372.00 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162456
Principal investigator 1 Abbott Laboratories $46.47 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162458
Principal investigator 1 Abbott Laboratories $158.00 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162462
Principal investigator 1 Abbott Laboratories $13.95 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162464
Principal investigator 1 Abbott Laboratories $1.40 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162466
Principal investigator 1 Abbott Laboratories $960.00 10/17/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162468
Principal investigator 1 Abbott Laboratories $82.50 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162406
Principal investigator 1 Abbott Laboratories $320.85 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162408
Principal investigator 1 Abbott Laboratories $17.40 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162410
Principal investigator 1 Abbott Laboratories $1,317.90 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162412
Principal investigator 1 Abbott Laboratories $26.25 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162414
Principal investigator 1 Abbott Laboratories $9.00 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162418
Principal investigator 1 Abbott Laboratories $13.00 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162420
Principal investigator 1 Abbott Laboratories $58.50 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162422
Principal investigator 1 Abbott Laboratories $71.40 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162424
Principal investigator 1 Abbott Laboratories $211.20 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162426
Principal investigator 1 Abbott Laboratories $171.30 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162428
Principal investigator 1 Abbott Laboratories $17.70 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162430
Principal investigator 1 Abbott Laboratories $7.99 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162432
Principal investigator 1 Abbott Laboratories $36.75 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162434
Principal investigator 1 Abbott Laboratories $14,999.70 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162436
Principal investigator 1 Abbott Laboratories $555.00 10/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162440
Principal investigator 1 SANOFI US SERVICES INC. $500.00 10/14/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226138055
Principal investigator 1 Dexcom, Inc. $3,000.00 10/07/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
MULTI-SESSION EVALUATION OF THE INVESTIGATIONAL DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM IN ADULT PARTICIPANTS No dispute reported 06/30/2026 1250961528
Principal investigator 1 Dexcom, Inc. $4,000.00 10/07/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
MULTI-SESSION EVALUATION OF THE INVESTIGATIONAL DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM IN ADULT PARTICIPANTS No dispute reported 06/30/2026 1250961532
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $9,123.00 10/02/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225414006
Principal investigator 1 Senseonics, Incorporated $1,676.35 09/18/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851847
Principal investigator 1 Senseonics, Incorporated $91.00 09/18/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851849
Principal investigator 1 Senseonics, Incorporated $200.00 09/18/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851851
Principal investigator 1 Dexcom, Inc. $3,000.00 09/16/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM SURVIVABILITY AND DATA DELIVERY RELIABILITY IN ADULTS AND PEDIATRICS WITH TYPE 1 AND TYPE 2 DIABETES No dispute reported 06/30/2026 1250961516
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,406.00 09/09/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a No dispute reported 06/30/2026 1225414860
Principal investigator 1 SANOFI US SERVICES INC. $16,000.00 09/08/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226138040
Principal investigator 1 Dexcom, Inc. $57,760.00 09/03/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
MULTI-SESSION EVALUATION OF THE INVESTIGATIONAL DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM IN ADULT PARTICIPANTS No dispute reported 06/30/2026 1250961524
Principal investigator 1 Dexcom, Inc. $3,000.00 08/19/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM SURVIVABILITY AND DATA DELIVERY RELIABILITY IN ADULTS AND PEDIATRICS WITH TYPE 1 AND TYPE 2 DIABETES No dispute reported 06/30/2026 1250961522
Principal investigator 1 Senseonics, Incorporated $1,345.00 07/31/2025 Non-covered Recipient Entity
ADVARRA
Senseonics CPT-0045 No dispute reported 06/30/2026 1249851777
Principal investigator 1 Dexcom, Inc. $26,984.00 07/28/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM SURVIVABILITY AND DATA DELIVERY RELIABILITY IN ADULTS AND PEDIATRICS WITH TYPE 1 AND TYPE 2 DIABETES No dispute reported 06/30/2026 1250961518
Principal investigator 1 Dexcom, Inc. $21,835.00 07/28/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
MULTI-SESSION EVALUATION OF THE INVESTIGATIONAL DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM IN ADULT PARTICIPANTS No dispute reported 06/30/2026 1250961520
Principal investigator 1 SANOFI US SERVICES INC. $16,000.00 07/21/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226137992
Principal investigator 1 Novo Nordisk AS $326.25 07/18/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES
NN9535-4352 No dispute reported 06/30/2026 1213827860
Principal investigator 1 Dexcom, Inc. $42,844.00 07/08/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM SURVIVABILITY AND DATA DELIVERY RELIABILITY IN ADULTS AND PEDIATRICS WITH TYPE 1 AND TYPE 2 DIABETES No dispute reported 06/30/2026 1250961526
Principal investigator 1 Sequel Med Tech, LLC $69,904.10 06/27/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES PC
twiist Initial Experience Study No dispute reported 06/30/2026 1243744094
Principal investigator 1 Eli Lilly and Company $141,959.00 06/10/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) No dispute reported 06/30/2026 1187875989
Principal investigator 1 Dexcom, Inc. $49,460.00 05/13/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM SURVIVABILITY AND DATA DELIVERY RELIABILITY IN ADULTS AND PEDIATRICS WITH TYPE 1 AND TYPE 2 DIABETES No dispute reported 06/30/2026 1250961514
Principal investigator 1 Medtronic, Inc. $2,500.00 05/06/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
CIP341 IMPACT2 No dispute reported 06/30/2026 1192322983
Principal investigator 1 Novo Nordisk AS $804.37 04/21/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES
NN9535-4352 No dispute reported 06/30/2026 1213710223
Principal investigator 1 Novo Nordisk AS $242.72 04/21/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES
NN9535-4352 No dispute reported 06/30/2026 1213828639
Principal investigator 1 Eli Lilly and Company $66.33 04/01/2025 Covered Recipient Teaching Hospital
KFH - SANTA CLARA
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187874545
Principal investigator 1 Dexcom, Inc. $60,600.00 03/25/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM SURVIVABILITY AND DATA DELIVERY RELIABILITY IN ADULTS AND PEDIATRICS WITH TYPE 1 AND TYPE 2 DIABETES No dispute reported 06/30/2026 1250961508
Principal investigator 1 Eli Lilly and Company $3,943.17 03/25/2025 Covered Recipient Teaching Hospital
KFH - SANTA CLARA
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187873729
Principal investigator 1 Sequel Med Tech, LLC $7,200.00 03/14/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES PC
twiist Initial Experience Study No dispute reported 06/30/2026 1243743284
Principal investigator 1 Abbott Laboratories $14.80 03/13/2025 Non-covered Recipient Entity
American Diabetes Association
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248148800
Principal investigator 1 Abbott Laboratories $55.00 03/13/2025 Non-covered Recipient Entity
American Diabetes Association
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248148802
Principal investigator 1 Senseonics, Incorporated $672.10 03/06/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0045 No dispute reported 06/30/2026 1249851843
Principal investigator 1 Senseonics, Incorporated $150.00 03/06/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0045 No dispute reported 06/30/2026 1249851845
Principal investigator 1 Sequel Med Tech, LLC $32,908.80 03/01/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES PC
twiist Initial Experience Study No dispute reported 06/30/2026 1243743278
Principal investigator 1 Dexcom, Inc. $17,795.00 02/25/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM SURVIVABILITY AND DATA DELIVERY RELIABILITY IN ADULTS AND PEDIATRICS WITH TYPE 1 AND TYPE 2 DIABETES No dispute reported 06/30/2026 1250961512
Principal investigator 1 Eli Lilly and Company $494.10 02/25/2025 Covered Recipient Teaching Hospital
KFH - SANTA CLARA
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187873733
Principal investigator 1 Medtronic, Inc. $202.00 02/21/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
CIP341 IMPACT2 No dispute reported 06/30/2026 1192322981
Principal investigator 1 Medtronic, Inc. $485.00 02/14/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
CIP341 IMPACT2 No dispute reported 06/30/2026 1192322979
Principal investigator 1 Senseonics, Incorporated $672.10 02/06/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0045 No dispute reported 06/30/2026 1249851835
Principal investigator 1 Senseonics, Incorporated $91.00 02/06/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0045 No dispute reported 06/30/2026 1249851837
Principal investigator 1 Senseonics, Incorporated $150.00 02/06/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0045 No dispute reported 06/30/2026 1249851839
Principal investigator 1 Senseonics, Incorporated $91.00 02/06/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES, P.C
Senseonics CTP-0045 No dispute reported 06/30/2026 1249851841
Principal investigator 1 Dexcom, Inc. $3,000.00 02/04/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates, Inc.
Evaluation of the Investigational Dexcom Continuous Monitoring (CGM) Sensor in Adult and Pediatric Subjects No dispute reported 06/30/2026 1250961510
Principal investigator 1 Novo Nordisk AS $374.35 01/31/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES
NN9535-4352 No dispute reported 06/30/2026 1213720274
Principal investigator 1 Eli Lilly and Company $121,505.00 01/07/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187875275
Principal investigator 1 Eli Lilly and Company $42,198.00 01/07/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187877123
Principal investigator 1 Eli Lilly and Company $214,526.00 01/06/2025 Non-covered Recipient Entity
ATLANTA DIABETES ASSOCIATES
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187877763
Principal investigator 1 Dompe Farmaceutici S.p.A. $185.76 01/05/2025 Non-covered Recipient Entity
Atlanta Diabetes Associates
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. No dispute reported 06/30/2026 1248397503